Cargando…

A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations

A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mammone, Francesca Romana, Zanitti, Leo, Puxeddu, Michela, La Regina, Giuseppe, Silvestri, Romano, Borioni, Anna, Cirilli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824232/
https://www.ncbi.nlm.nih.gov/pubmed/36615620
http://dx.doi.org/10.3390/molecules28010431
_version_ 1784866359180525568
author Mammone, Francesca Romana
Zanitti, Leo
Puxeddu, Michela
La Regina, Giuseppe
Silvestri, Romano
Borioni, Anna
Cirilli, Roberto
author_facet Mammone, Francesca Romana
Zanitti, Leo
Puxeddu, Michela
La Regina, Giuseppe
Silvestri, Romano
Borioni, Anna
Cirilli, Roberto
author_sort Mammone, Francesca Romana
collection PubMed
description A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditions is usually challenging. Herein, a direct and highly selective ultra-high-performance liquid chromatographic method for determining the assay and related substances content in medicinal products containing rosuvastatin calcium salt (RSV) is presented. RSV is used to treat high cholesterol levels and prevent heart attacks and strokes. The most engaging feature of this method was the baseline separation of all organic related substances listed in the European Pharmacopoeia (EP) monograph for the RSV tablets, achieved for the first time in less than 15 min using the Acquity BEH C18 (100 mm × 2.1 mm, 1.7 μm) column under reversed-phase isocratic conditions. The mobile phase adopted for the chemo-selective analysis does not contain buffers but instead contains trifluoroacetic as an acid additive. The chromatographic method was validated according to the guidelines of the International Conference on Harmonization (ICH) and proved to be linear, precise and accurate for determining the content of RSV and related chiral substances in tablet formulations.
format Online
Article
Text
id pubmed-9824232
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98242322023-01-08 A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations Mammone, Francesca Romana Zanitti, Leo Puxeddu, Michela La Regina, Giuseppe Silvestri, Romano Borioni, Anna Cirilli, Roberto Molecules Article A key step in the development of medicinal products is the research and validation of selective and sensitive analytical methods for the control of impurities from synthesis and degradation. As most impurities are similar in structure to the drug substance, the achievement of chemo-selective conditions is usually challenging. Herein, a direct and highly selective ultra-high-performance liquid chromatographic method for determining the assay and related substances content in medicinal products containing rosuvastatin calcium salt (RSV) is presented. RSV is used to treat high cholesterol levels and prevent heart attacks and strokes. The most engaging feature of this method was the baseline separation of all organic related substances listed in the European Pharmacopoeia (EP) monograph for the RSV tablets, achieved for the first time in less than 15 min using the Acquity BEH C18 (100 mm × 2.1 mm, 1.7 μm) column under reversed-phase isocratic conditions. The mobile phase adopted for the chemo-selective analysis does not contain buffers but instead contains trifluoroacetic as an acid additive. The chromatographic method was validated according to the guidelines of the International Conference on Harmonization (ICH) and proved to be linear, precise and accurate for determining the content of RSV and related chiral substances in tablet formulations. MDPI 2023-01-03 /pmc/articles/PMC9824232/ /pubmed/36615620 http://dx.doi.org/10.3390/molecules28010431 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mammone, Francesca Romana
Zanitti, Leo
Puxeddu, Michela
La Regina, Giuseppe
Silvestri, Romano
Borioni, Anna
Cirilli, Roberto
A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title_full A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title_fullStr A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title_full_unstemmed A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title_short A Novel Validated UHPLC Method for the Estimation of Rosuvastatin and Its Complete Impurity Profile in Tablet Formulations
title_sort novel validated uhplc method for the estimation of rosuvastatin and its complete impurity profile in tablet formulations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9824232/
https://www.ncbi.nlm.nih.gov/pubmed/36615620
http://dx.doi.org/10.3390/molecules28010431
work_keys_str_mv AT mammonefrancescaromana anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT zanittileo anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT puxeddumichela anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT lareginagiuseppe anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT silvestriromano anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT borionianna anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT cirilliroberto anovelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT mammonefrancescaromana novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT zanittileo novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT puxeddumichela novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT lareginagiuseppe novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT silvestriromano novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT borionianna novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations
AT cirilliroberto novelvalidateduhplcmethodfortheestimationofrosuvastatinanditscompleteimpurityprofileintabletformulations